1
|
Maldonado-Mendoza J, Ramírez-Amador V, Anaya-Saavedra G. Primary oral and sinonasal mucosal melanomas in Latin America: a systematic review. Int J Oral Maxillofac Surg 2024; 53:449-460. [PMID: 38040520 DOI: 10.1016/j.ijom.2023.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 11/03/2023] [Accepted: 11/09/2023] [Indexed: 12/03/2023]
Abstract
Primary oral and sinonasal mucosal melanomas (POSNMMs) are aggressive neoplasms with limited therapeutic alternatives. The aim of this review was to characterize the demographic, clinical, immunohistochemical, and molecular information regarding these tumors in the Latin American population. Articles published in English, Spanish, or Portuguese (1990-2022) retrieved from the PubMed/MEDLINE, Scopus, CAS, Web of Science, EBSCO, and Google Academic databases were included. Thirty-three studies, with a total of 1212 cases, were identified. Clinicopathological data were available for 870 cases and immunohistochemical and/or molecular information for 342. Nineteen studies (57.6%) reported cases of oral melanoma, three (9.1%) sinonasal melanoma, and 11 (33.3%) oral and sinonasal melanoma. Fifteen studies (45.5%) provided only clinicopathological data, 12 (36.4%) reported only immunohistochemical data, two (6.1%) shared clinicopathological and immunohistochemical data, one (3.0%) offered clinicopathological, immunohistochemical, and molecular data, one (3.0%) provided immunohistochemical and molecular data, one (3.0%) clinicopathological and molecular data, and one (3.0%) only molecular data. The mean age of individuals with POSNMMs was 58 years, and slightly more were male (male 51.3%, female 48.7%). In Latin America, POSNMMs are a rare but aggressive malignancy with a poor prognosis and limited treatment options. Although molecular data and targeted therapy are still being researched, data from Latin America indicate the need for multicenter collaborative clinical trials to unite individual and isolated efforts.
Collapse
Affiliation(s)
- J Maldonado-Mendoza
- Oral Pathology and Medicine Master Program, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico
| | - V Ramírez-Amador
- Oral Pathology and Medicine Master Program, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico
| | - G Anaya-Saavedra
- Oral Pathology and Medicine Master Program, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.
| |
Collapse
|
2
|
Yang Y, Sanders AJ, Dou QP, Jiang DG, Li AX, Jiang WG. The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers. Cancers (Basel) 2021; 13:cancers13205187. [PMID: 34680335 PMCID: PMC8533996 DOI: 10.3390/cancers13205187] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 02/08/2023] Open
Abstract
Simple Summary ALCAM (activated leukocyte cell adhesion molecule) is an important regulator in human cancers, particularly solid tumours. Its expression in cancer tissues has prognostic values depending on cancer types and is also linked to distant metastases. A truncated form, soluble form of ALCAM (sALCAM) in circulation has been suggested to be a prognostic indicator and a potential therapeutic tool. This article summarises recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections and therapeutic values. Abstract Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a cell adhesion protein that is found in multiple cell types. ALCAM has multiple and diverse roles in various physiological and pathological conditions, including inflammation and cancer. There has been compelling evidence of ALCAM’s prognostic value in solid cancers, indicating that it is a potential therapeutic target. The present article overviews the recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections in cancer and therapeutic values.
Collapse
Affiliation(s)
- Yiming Yang
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
| | - Andrew J. Sanders
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
- Correspondence: (A.J.S.); (W.G.J.)
| | - Q. Ping Dou
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
- Departments of Oncology, Pharmacology and Pathology School of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201-2013, USA
| | - David G. Jiang
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
- Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, Aylesbury HP21 8AL, UK
| | - Amber Xinyu Li
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
| | - Wen G. Jiang
- School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK; (Y.Y.); (Q.P.D.); (D.G.J.); (A.X.L.)
- Correspondence: (A.J.S.); (W.G.J.)
| |
Collapse
|
3
|
Li W, Xu C, Wang K, Ding Y, Ding L. Non-tight junction-related function of claudin-7 in interacting with integrinβ1 to suppress colorectal cancer cell proliferation and migration. Cancer Manag Res 2019; 11:1443-1451. [PMID: 30863155 PMCID: PMC6389015 DOI: 10.2147/cmar.s188020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Purpose We conducted a preliminarily exploration of the role and possible mechanism of the non-tight junction-related function of claudin-7 in the occurrence and development of colorectal cancer. Methods We selected the colorectal cancer cell line HCT116, constructed a stably transfected claudin-7 knockdown cell line via RNAi and lentiviral infection, and determined the claudin-7 knockdown efficiency. We assessed the biological behavior changes (cell viability, apoptosis, and migration) in the stably transfected HCT116 cells and observed structural changes in the tight junction by transmission electron microscopy. We used a subcutaneous tumor formation model to assess the tumorigenicity of HCT116 cells after claudin-7 knockdown. We assessed the expression and localization of integrinβ1 in the stably transfected cell line by immunofluorescence staining and investigated the interaction between integrinβ1 and claudin-7 by co-immunoprecipitation. Results After the knockdown of claudin-7 the expression, the viability and migration ability of HCT116 cells increased and apoptosis decreased. Transmission electron microscopy indicated that the intercellular tight junction structure did not change substantially. Furthermore, the tumor growth in nude mice was enhanced. Immunofluorescence staining showed that integrinβ1 and claudin-7 were co-expressed and co-localized on the cell membrane, and immunoprecipitation suggested that claudin-7 interacts with integrinβ1. Conclusion Claudin-7 may inhibit the proliferation and migration of tumor cells by interacting with integrinβ1, subsequently participating in the development of colorectal cancer.
Collapse
Affiliation(s)
- Wenjing Li
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China, .,Binzhou Medical University Hospital, Binzhou, People's Republic of China
| | - Chang Xu
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China,
| | - Kun Wang
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China,
| | - Yuhan Ding
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China,
| | - Lei Ding
- Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China,
| |
Collapse
|
4
|
A preliminary immunohistochemical study of signal transducer and activator of transcription (STAT) proteins in primary oral malignant melanoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125:164-171. [DOI: 10.1016/j.oooo.2017.10.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 10/14/2017] [Accepted: 10/23/2017] [Indexed: 02/03/2023]
|
5
|
Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, Gogas H, Lombardi D, Maroldi R, Nicolai P, Ravanelli M, Vanella V. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol 2017; 112:136-152. [DOI: 10.1016/j.critrevonc.2017.01.019] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 12/27/2016] [Accepted: 01/31/2017] [Indexed: 02/08/2023] Open
|
6
|
Capaldo CT, Nusrat A. Claudin switching: Physiological plasticity of the Tight Junction. Semin Cell Dev Biol 2015; 42:22-9. [PMID: 25957515 DOI: 10.1016/j.semcdb.2015.04.003] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 04/15/2015] [Accepted: 04/16/2015] [Indexed: 01/22/2023]
Abstract
Tight Junctions (TJs) are multi-molecular complexes in epithelial tissues that regulate paracellular permeability. Within the TJ complex, claudins proteins span the paracellular space to form a seal between adjacent cells. This seal allows regulated passage of ions, fluids, and solutes, contingent upon the complement of claudins expressed. With as many as 27 claudins in the human genome, the TJ seal is complex indeed. This review focuses on changes in claudin expression within the epithelial cells of the gastrointestinal tract, where claudin differentiation results in several physiologically distinct TJs within the lifetime of the cell. We also review mechanistic studies revealing that TJs are highly dynamic, with the potential to undergo molecular remodeling while structurally intact. Therefore, physiologic Tight Junction plasticity involves both the adaptability of claudin expression and gene specific retention in the TJ; a process we term claudin switching.
Collapse
Affiliation(s)
- Christopher T Capaldo
- Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, United States
| | - Asma Nusrat
- Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, United States; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States.
| |
Collapse
|
7
|
Tlholoe MM, Khammissa RAG, Bouckaert M, Altini M, Lemmer J, Feller L. Oral mucosal melanoma: some pathobiological considerations and an illustrative report of a case. Head Neck Pathol 2015; 9:127-34. [PMID: 24496654 PMCID: PMC4382483 DOI: 10.1007/s12105-014-0526-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Accepted: 01/28/2014] [Indexed: 12/17/2022]
Abstract
Oral mucosal melanoma is a relatively rare malignancy with an aggressive clinico-pathological behaviour. The mean 5-year survival rate is about 15 %. It arises primarily from melanocytes found in the basal cell layer of the epithelium, but may sometimes arise from melanocytes residing in the lamina propria. The pathogenesis is complex, and few of the molecular mechanisms underlying the development of oral mucosal melanoma have been defined. The extraneous risk factors associated with oral mucosal melanoma, if any, are unknown. Oral mucosal melanomas account for about 25 % of all mucosal melanomas of the head and neck, and exhibit a profile of cytogenetic alterations, and a pathobiological behaviour and clinical course different from that of cutaneous melanomas. As they are usually painless and grow quickly, as a rule, they are diagnosed late in the course of the disease when the lesions are already large and have metastasized to regional lymph nodes. In this paper we discuss some aspects of the pathobiology of oral mucosal melanoma, and present an illustrative case report.
Collapse
Affiliation(s)
- M. M. Tlholoe
- />Department of Maxillofacial Oral Surgery, University of Limpopo, Medunsa Campus, Pretoria, South Africa
| | - R. A. G. Khammissa
- />Department of Periodontology and Oral Medicine, University of Limpopo, Medunsa Campus, Pretoria, South Africa
| | - M. Bouckaert
- />Department of Maxillofacial Oral Surgery, University of Limpopo, Medunsa Campus, Pretoria, South Africa
| | - M. Altini
- />Department of Pathology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
| | - J. Lemmer
- />Department of Periodontology and Oral Medicine, University of Limpopo, Medunsa Campus, Pretoria, South Africa
| | - L. Feller
- />Department of Periodontology and Oral Medicine, University of Limpopo, Medunsa Campus, Pretoria, South Africa
| |
Collapse
|
8
|
Warszawik-Hendzel O, Słowińska M, Olszewska M, Rudnicka L. Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management. J Dermatol Case Rep 2014; 8:60-6. [PMID: 25324906 DOI: 10.3315/jdcr.2014.1175] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 09/13/2014] [Indexed: 01/06/2023]
Abstract
Primary mucosal melanoma of the oral cavity is an exceedingly rare neoplasm which is estimated to comprise 1-2% of all oral malignancies. In contrast to cutaneous melanomas, the risk factors and pathogenesis are poorly understood. The predominate localization of primary oral melanoma is hard palate and maxillary alveolus. Dermoscopy may be utilized as an adjunctive tool in the clinical differential diagnosis of oral mucosal melanoma whenever the lesion is accessible with a dermoscope. Surgery is the mainstay of treatment, but it may be challenging depending on the location of the tumor within the oral cavity and its size. Adjuvant therapy with dacarbazine, platinum analogs, nitrosoureas and interleukin-2 have been utilized with low response rates. Imatinib may be effective for patients with with c-Kit gene mutations. Sunitinib and dasatinib have been reported effective in selected cases. Vemurafenib and dabrafenib are targeted agents for patients with BRAF mutation-positive melanoma. Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody and pembrolizumab, a monoclonal antibody targeting programmed death 1 receptor may be a feasible treatment option in patients with metastatic mucosal melanoma.
Collapse
Affiliation(s)
| | | | | | - Lidia Rudnicka
- Department of Dermatology, Medical University of Warsaw, Poland; ; Departmet of Neuropeptides, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
| |
Collapse
|